36 results about "Thoracic aortic aneurysm" patented technology

The present invention provides multilayered materials, such as films usable in particular in medical devices in the form of vascular grafts, biocompatible coverings, and / or inflatable bladders, prosthesis for the endoluminal treatment of aneurysms, particularly aortic aneurysms including both abdominal aortic aneurysms (AAA's) and thoracic aortic aneurysms (TAA's).

Topical cooling of spinal cord, brain, esophagus, etc. can be selectively and continuously carried out under convenient control without causing any changes in internal pressure of spinal cord cavity, brain pressure, etc. by inserting a catheter, which has no hole connecting to the outside and in which a heat-cooling medium is circulated in its inner space to thereby cool a topical site; into the spinal cord, the epidural cavity, the subdural cavity or the subarachnoid cavity of the brain or the esophageal cavity and placing therein and then circulating the heat / cooling medium within the inner space of the catheter; or using a device composed of a heat absorption member in the form of a catheter, a heat insulation member and a heat radiation member, inserting the heat absorption member in the form of a catheter into the spinal cord, the epidural cavity, the subdural cavity or the subarachnoid cavity of the brain or the esophageal cavity and placing therein and then absorbing heat from the heat absorption member and radiating the heat from the heat radiation member via the heat insulation member, thereby contributing to the treatment of spinal diseases including prevention of paraplegia accompanying thoracic aortic aneurysm surgery and the treatment of brain injury, esophageal injury and so on.

The present invention refers to an In vitro method for screening for subjects at risk of developing thoracic aortic aneurysm (TAA) or a disease causing TAA comprising: (a) measuring the expression pattern or level of at least A Disintegrin And Metalloproteinase with Thrombospondin Motifs 1 (ADAMTS1) obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least ADAMTS1 of the subjects to be screened with an already established expression pattern or level, wherein reduced expression of at least ADAMTS1 is indicative of a thoracic aortic aneurysm (TAA).

The present invention provides methods of treating aneurysmal dilatation, blood vessel wall weakness, and specifically abdominal aortic aneurysm and thoracic aneurysm by inhibiting MMPs and ADAM-IO. Such compounds are useful in the in vitro study of the role of MMPs and ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more MMPs or ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm. The invention also comprises methods of treating aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm utilizing the compounds of the invention in conjunction with inhibitors of angiotensin II, including angiotensin II receptor blockers and angiotensin converting enzyme inhibitors, and cyclophillin inhibitors.

The present invention provides a compound represented by the formula (I):wherein each symbol is as defined in the specification, or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm (e.g. abdominal aortic aneurysm, thoracic aortic aneurysm, thoracoabdominal aortic aneurysm etc.), endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.

The invention belongs to the field of medicine, and relates to application of an intermittent low-oxygen system in a thoracic aortic aneurysm treating device. The invention discloses the new application of the intermittent low-oxygen system which is used for treating the thoracic aortic aneurysm of mammals. It is proved that the intermittent low-oxygen system has an obvious treatment effect on the thoracic aortic aneurysm of the mammals, so that a new approach is provided for the clinic treatment of the thoracic aortic aneurysm. Besides, the invention further provides a device or equipment for treating the thoracic aortic aneurysm, and the device or equipment contains the intermittent low-oxygen system.

The invention discloses a thoracic aortic aneurysm coated stent which comprises a metal stent and a polymer film which is sleeved on the external side of the metal stent. The metal stent comprises a laser cutting bare stent with one end located outside the polymer film, a laser cutting stent and a heat treatment stent; the laser cutting stent and the heat treatment stent are located inside the polymer film; the metal stent is in a waved structure; an overlapping part of the metal stent and the polymer film is in suture connection with the polymer film; and one end of the laser cutting bare stent, which is located on the external of the polymer film, is provided with a plurality of hanging rings which are used for connecting with a conveying system. According to the thoracic aortic aneurysm coated stent, a minimally invasive way can be employed to treat a thoracic aortic aneurysm to enable an aneurysm cavity and a parent artery lumen to be immediately isolated to repair lesion blood vessels. The invention also discloses a thoracic aortic aneurysm minimally invasive treatment system with the thoracic aortic aneurysm coated stent.

Stent-grafts for treating thoracic aortic aneurysms and abdominal aortic aneurysms include graft portions having inflatable channels and graft extensions. The graft extensions include an undulating wire stent and porous, but substantially fluid impermeable, polytetrafluoroethylene (PTFE) graft materials.

Thoracic aortic aneurysm is a common and lethal disease that requires regular imaging surveillance to determine timing of surgical repair and prevent major complications such as rupture. Current cross-sectional imaging surveillance techniques, largely based on computed tomography angiography (CTA) or magnetic resonance angiography (MRA), are focused on measurement of maximal aortic diameter, although this approach is limited to fixed anatomic positions and is prone to significant measurement error. The present techniques demonstrate novel approaches (generally termed herein “Vascular Deformation Mapping (VDM)”) for assessing changes in aortic dimensions. The present techniques quantify three-dimensional changes in the anatomic dimensions of a vessel through a process that involves non-rigid co-registration of serial imaging data and quantification of vascular deformation on a 3D surface model using some derivation of the spatial deformations resulting from the optimized spatial transform.